News
HGP – AUVI-Q® (epinephrine injection, USP) Available in Canada Starting September 7
– Health Canada issues Interim Order authorizing importation and sale of U.S. FDA-approved AUVI-Q (0.15 mg and 0.3 mg) to patients in need
RICHMOND, VA. (August 29, 2018) – Kaléo, a privately-held pharmaceutical company, today announced that AUVI-Q® (epinephrine injection, USP) will be available in Canada starting September 7.
In response to the ongoing shortage of epinephrine auto-injectors in Canada, Minister of Health Ginette Petitpas Taylor signed an Interim Order, authorizing the importation and sale of U.S. Food and Drug Administration (FDA) approved AUVI-Q auto-injectors to patients at risk for, or have a history of, serious allergic reactions. Kaléo is working closely with Health Canada, provincial and territorial health authorities, as well as a distributor, to equitably distribute AUVI-Q to pharmacies across the country.
To read more click here.